ArticleUrology2025
Sodium-Glucose Transport Protein 2 Inhibitor Use Is Not Associated With Increased Risk of Inflatable Penile Prosthesis Infections Among Diabetic Patients.
Article in Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between SGLT2 inhibitor use and Fournier's gangrene after genital or perineal surgery: a retrospective cohort study.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo determine whether diabetic patients taking sodium-glucose transport protein 2 inhibitors (SGLT2i) are at increased risk of inflatable penile prosthesis (IPP) infections, given the association of SGLT2i with higher rates of urinary tract and genital infections, and to assess the frequency of IPP infections in this patient population. MATERIALS AND
methodsWe performed a retrospective review of all diabetic men who underwent IPP placement utilizing the IBM MarketScan insurance claims database between 2011-2021. Demographic data, including age, smoking status, and obesity, were obtained. An IPP infection was identified based on ICD-9/10 and CPT codes. Multivariable analyses were performed to assess the likelihood of IPP infections.
resultsA total of 2838 patients were identified. The median age was 61 years (55-66 years), with 61.0% classified as obese and 18.9% identified as smokers. Among these patients, 883 (31.1%) were on an SGLT2i. At a median follow-up of 25 months (10-49 months), 82 (2.9%) patients developed an infection, including 28 (3.2%) patients on SGLT2i and 54 (2.8%) patients on other diabetes medications. SGLT2i use was associated with a nonsignificant increase in the hazard ratio (HR) for infection [1.26 (P = .39)], while obesity and smoking were associated with statistically significant HRs [2.02 (P = .02) and 2.20 (P < .01), respectively].
conclusionSLGT2i likely does not have a large effect on rates of IPP infection and may be continued perioperatively. Smoking cessation and weight loss may decrease the risk of IPP infections in diabetic patients, and counseling on this should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.